Compare AGRO & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRO | COLL |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 2015 |
| Metric | AGRO | COLL |
|---|---|---|
| Price | $10.15 | $37.27 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $8.17 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 470.7K | 387.1K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | $19.91 | N/A |
| P/E Ratio | $37.52 | ★ $21.55 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $6.89 | $23.23 |
| 52 Week High | $11.79 | $50.79 |
| Indicator | AGRO | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 70.88 | 21.42 |
| Support Level | $8.58 | $34.30 |
| Resistance Level | N/A | $39.85 |
| Average True Range (ATR) | 0.35 | 1.61 |
| MACD | 0.10 | -0.83 |
| Stochastic Oscillator | 89.86 | 9.89 |
Adecoagro SA is a Luxembourg-based agricultural company. It is involved in a wide range of businesses, including farming crops and other agricultural products, dairy operations sugar, ethanol, energy production, and land transformation. The group operates in two lines of business, namely, Farming and Sugar, Ethanol and Energy. The Farming is further comprised of three reportable segments: Crops, Rice and Dairy. Sugar, Ethanol and Energy Segment, consists of cultivating sugarcane, which is processed in owned sugar mills, transformed into ethanol, sugar and electricity, in addition to biomethane and then marketed.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.